{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:59:43Z","timestamp":1785517183077,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41375-025-02778-1","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T06:56:11Z","timestamp":1759388171000},"page":"2618-2621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib"],"prefix":"10.1038","volume":"39","author":[{"given":"Alessandra","family":"Tedeschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Frustaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7755-818X","authenticated-orcid":false,"given":"Pierantonio","family":"Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5678-6175","authenticated-orcid":false,"given":"Giorgio","family":"Minotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"2778_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia. JAMA. 2023;329:918\u201332.","journal-title":"JAMA"},{"key":"2778_CR2","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1200\/OP.23.00770","volume":"20","author":"BD Cheson","year":"2024","unstructured":"Cheson BD, Shadman M. Current approaches and novel agents in the treatment of chronic lymphocytic leukemia. J Clin Oncol Oncol Pract. 2024;20:1360\u201366.","journal-title":"J Clin Oncol Oncol Pract"},{"key":"2778_CR3","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","volume":"35","author":"B Eichhorst","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU, Kater AP, Gregor M, Hallek M, et al. ESMO clinical practice guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35:762\u201368.","journal-title":"Ann Oncol"},{"key":"2778_CR4","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1182\/blood.2024024631","volume":"144","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024;144:1924\u201335.","journal-title":"Blood"},{"key":"2778_CR5","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","volume":"25","author":"M F\u00fcrstenau","year":"2024","unstructured":"F\u00fcrstenau M, Kater AP, Robrecht S, Zhang C, Gregor M, Thornton P, et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2024;25:744\u201359.","journal-title":"Lancet Oncol"},{"key":"2778_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bneo.2024.100034","volume":"1","author":"N Timofeeva","year":"2024","unstructured":"Timofeeva N, Jain N, Gandhi V. Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice. Blood Neoplasia. 2024;1:1\u201321.","journal-title":"Blood Neoplasia"},{"key":"2778_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41408-021-00429-z","volume":"11","author":"P Lu","year":"2021","unstructured":"Lu P, Wang S, Franzen CA, Venkataraman G, McClure R, Li L, et al. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021;11:39\u201359.","journal-title":"Blood Cancer J"},{"key":"2778_CR8","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","volume":"139","author":"CS Tam","year":"2022","unstructured":"Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139:3278\u201389.","journal-title":"Blood"},{"key":"2778_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"AP Kater","year":"2022","unstructured":"Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin MD, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1:1\u201312.","journal-title":"NEJM Evid"},{"key":"2778_CR10","doi-asserted-by":"publisher","first-page":"7535","DOI":"10.1200\/JCO.2023.41.16_suppl.7535","volume":"41","author":"PM Barr","year":"2023","unstructured":"Barr PM, Allan JN, Siddiqui T, Wierda WG, Tam CSL, Moreno C, et al. Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study. J Clin Oncol. 2023;41:7535.","journal-title":"J Clin Oncol"},{"key":"2778_CR11","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.1200\/JCO.2024.42.16_suppl.7009","volume":"42","author":"WG Wierda","year":"2024","unstructured":"Wierda WG, Jacobs R, Barr PM, Allan JN, Siddiqi T, Tedeschi A, et al. Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study. J Clin Oncol. 2024;42:7009.","journal-title":"J Clin Oncol"},{"key":"2778_CR12","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1200\/JCO.22.02283","volume":"41","author":"T Munir","year":"2023","unstructured":"Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, et al. Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study. J Clin Oncol. 2023;41:3689\u201399.","journal-title":"J Clin Oncol"},{"key":"2778_CR13","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","volume":"24","author":"CU Niemann","year":"2023","unstructured":"Niemann CU, Munir T, Moreno C, Owen C, Follows GA, Benjamini O, et al. Fixed-duration ibrutinib\u2013venetoclax versus chlorambucil\u2013obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:1423\u201333.","journal-title":"Lancet Oncol"},{"key":"2778_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJMoa2409804","volume":"392","author":"JR Brown","year":"2025","unstructured":"Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392:748\u201362.","journal-title":"N Engl J Med"},{"key":"2778_CR15","unstructured":"Munir T, Hern\u00e1ndez-Rivas JA, Tedeschi A, Ysebaert L, Allen J, Schioppa C, et al. Cross-study comparison of ibrutinib in combination with venetoclax (I+V) vs acalabrutinib in combination with venetoclax (A+V) in subjects with previously untreated chronic lymphocytic leukemia (CLL). Poster presentation at 2025 European Hematology Association (EHA) Congress; June 12\u201315, 2025."},{"key":"2778_CR16","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39:3853\u201365.","journal-title":"J Clin Oncol"},{"key":"2778_CR17","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41388-017-0066-2","volume":"37","author":"L Patrussi","year":"2018","unstructured":"Patrussi L, Capitani N, Cattaneo F, Manganaro N, Gamberucci A, Frezzato F, et al. p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from \u03b2-arrestin at early endosomes. Oncogene. 2018;37:1534\u201350.","journal-title":"Oncogene"},{"key":"2778_CR18","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1158\/1078-0432.CCR-22-3217","volume":"29","author":"AF Alsadhan","year":"2023","unstructured":"Alsadhan AF, Chen J, Gaglione EM, Underbayev C, Tuma PL, Tian X, et al. CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with Inferior progression-free survival on BTK Inhibitor Therapy. Clin Cancer Res. 2023;29:3612\u201321.","journal-title":"Clin Cancer Res"},{"key":"2778_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.144","volume":"8","author":"I Innocenti","year":"2024","unstructured":"Innocenti I, Mosca A, Tommaso A, Galitzia A, Scarf\u00f2 L, Morelli F, et al. Kinetics of lymphocytosis in na\u00efve chronic lymphocytic leukemia patients treated with covalent Bruton\u2019s tyrosine kinase inhibitors: an Italian multicenter real-life experience. Hemasphere. 2024;8:e144.","journal-title":"Hemasphere"},{"key":"2778_CR20","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/leu.2017.32","volume":"31","author":"J Deng","year":"2017","unstructured":"Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS, et al. Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017;31:2075\u201384.","journal-title":"Leukemia"},{"key":"2778_CR21","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.2019004326","volume":"136","author":"MV Haselager","year":"2020","unstructured":"Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, et al. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020;136:2918\u201326.","journal-title":"Blood"},{"key":"2778_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood.2022018818","volume":"142","author":"JF Seymour","year":"2023","unstructured":"Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023;142:687\u201399.","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1038\/s41375-025-02793-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000}},{"DOI":"10.1038\/s41375-025-02824-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02778-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02778-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02778-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:06:24Z","timestamp":1785513984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02778-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2778"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02778-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the sentence beginning \u2018On the other hand, the data are quite...\u2019 in this article, the text \u2018over venetoclax\u2019 should have read \u2018over acalabrutinib\u2019. The original article has been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-025-02824-y","URL":"https:\/\/doi.org\/10.1038\/s41375-025-02824-y","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":13,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":14,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":15,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-025-02793-2","URL":"https:\/\/doi.org\/10.1038\/s41375-025-02793-2","order":16,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AT has received honoraria for participation in advisory boards from AbbVie, AstraZeneca, BeiGene, Johnson & Johnson, Lilly, and is a participant in speaker bureaus for AbbVie, BeiGene, and Johnson & Johnson. AMF has received honoraria for participation in advisory boards and has received sponsorships for congresses from AbbVie, AstraZeneca, BeiGene, Johnson & Johnson. PM is a participant in speaker bureaus for Johnson & Johnson. GM has received honoraria for participation in advisory boards from BeiGene, Incyte, Johnson & Johnson, Lilly, and Servier, and is a participant in speaker bureaus for AbbVie, BeiGene, and Johnson & Johnson.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}